论文部分内容阅读
目的 :探讨 bcl- 2基因在急性髓系白血病 (AML)中的表达与预后的关系。方法 :应用链亲和素 -胶体金原位杂交 (ISH- SAG)法检测 5 7例 AML 患者单个核细胞的 bcl- 2基因表达水平。结果 :5 7例 AML 患者不同程度表达 bcl- 2基因 ,范围从 0～ 98% ,其中初治组的阳性率为 4 6 .2 %(2 4 / 5 2 ) ,缓解组的阳性率为 4 0 .7% (11/ 2 7) ,难治复发组的阳性率为 10 0 % (15 / 15 ) ;难治复发组与初治组及缓解组之间差异均具有显著性 (P<0 .0 1) ,AML 各亚型之间表达无显著性差异 (P>0 .0 5 ) ;疗效分析发现 bcl- 2基因表达与临床缓解密切相关 ,阴性组缓解率 (76 .2 % )显著高于阳性组 (4 2 .1% ) (P<0 .0 5 )。结论 :bcl- 2基因过度表达对 AML 的预后有重要关系 ,可作为判断预后和合理制定治疗方案的重要依据。
Objective: To investigate the relationship between bcl-2 gene expression and prognosis in acute myeloid leukemia (AML). Methods: The expression of bcl-2 gene in 57 mononuclear cells from AML patients was detected by streptavidin-gold in situ hybridization (ISH-SAG). Results: A total of 57 AML patients expressed different degrees of bcl-2 gene, ranging from 0 to 98%. The positive rate of newly diagnosed AML patients was 46.2% (24/52), and the positive rate of remission patients was 4 The positive rate of refractory relapse was 100% (15/15) in patients with refractory or relapsed disease (P <0.05). The difference between the refractory and relapsed patients was significant .0 1). There was no significant difference between the subtypes of AML (P> 0.05). The curative effect analysis showed that the expression of bcl-2 gene was closely related to clinical remission, and the remission rate of negative group (76.2%) was significantly Higher than the positive group (42.1%) (P <0.05). Conclusion: The overexpression of bcl-2 gene plays an important role in the prognosis of AML. It may serve as an important basis for judging the prognosis and developing a reasonable treatment plan.